Literature DB >> 7589087

Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand.

B Bourrie1, M Bouaboula, J M Benoit, J M Derocq, M Esclangon, G Le Fur, P Casellas.   

Abstract

SR 31747A is a new sigma ligand eliciting immunosuppressive and anti-inflammatory properties. Here, we show that SR 31747A greatly enhances lipopolysaccharide (LPS)-induced systemic release of interleukin (IL)-10, while it inhibits the secretion of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma. In line with this finding, we also show by using quantitative reverse transcription-polymerase chain reaction analysis that SR 31747A increased LPS-induced IL-10 mRNA accumulation in spleen cells, whereas the level of both TNF-alpha and IFN-gamma mRNA was dramatically decreased. The enhancement of IL-10 production by SR 31747A treatment was also apparent in nude and severe-combined immunodeficient mice treated with LPS, clearly indicating that T and B cells were not involved. Finally, SR 31747A conferred protection against the lethal effect of LPS. The finding that SR 31747A strongly stimulates the synthesis of the natural anti-inflammatory cytokine IL-10, a property not observed with dexamethasone, provides new insights for the clinical use of this original compound, particularly in chronic inflammatory diseases where IL-10 is believed to be a pivotal regulatory component.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589087     DOI: 10.1002/eji.1830251026

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.

Authors:  B Oxombre; C Lee-Chang; A Duhamel; M Toussaint; M Giroux; M Donnier-Maréchal; P Carato; D Lefranc; H Zéphir; L Prin; P Melnyk; P Vermersch
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

3.  A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice.

Authors:  B Bourrié; J M Benoît; J M Derocq; M Esclangon; C Thomas; G Le Fur; P Casellas
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Sigma receptors suppress multiple aspects of microglial activation.

Authors:  Aaron A Hall; Yelenis Herrera; Craig T Ajmo; Javier Cuevas; Keith R Pennypacker
Journal:  Glia       Date:  2009-05       Impact factor: 7.452

Review 5.  Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Authors:  Halley M Oyer; Christina M Sanders; Felix J Kim
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

6.  Inhibitory effects of sigma-2 receptor agonists on T lymphocyte activation.

Authors:  Miguel A Iñiguez; Carmen Punzón; Raquel Nieto; Javier Burgueño; José M Vela; Manuel Fresno
Journal:  Front Pharmacol       Date:  2013-03-13       Impact factor: 5.810

Review 7.  Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities.

Authors:  Attila Szabo
Journal:  Front Immunol       Date:  2015-07-14       Impact factor: 7.561

8.  Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.

Authors:  Attila Szabo; Attila Kovacs; Ede Frecska; Eva Rajnavolgyi
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

Review 9.  Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases.

Authors:  Jia Jia; Jian Cheng; Cheng Wang; Xuechu Zhen
Journal:  Front Cell Neurosci       Date:  2018-09-20       Impact factor: 5.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.